CrushSCI.com
83.7Average days
70.5Median days
16Fastest days
205Longest days
2372025 publications

Paper Review Records

All Paper Review Records

18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

70 days

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9- associated MDS with phenotypic shift from AML to B-ALL

Authors
Yusuke Nakata; Anna Hiratsuka; Takeshi Yoroidaka; Wakana Takahashi; Itaru Nishikawa; Masataka Sakashita; Shinya Yamada; Hiroki Mizumaki; Akiyo Yoshida; Tatsuya Imi; Hiroyuki Maruyama; Hiroyuki Takamatsu; Kohei Hosokawa; Yasuhito Nannya; Seishi Ogawa; Toshihiro MiyamotoShow moreShow less
Affiliations
1. Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; 2. Division of Hematology, Keiju Kanazawa Hospital, Kanazawa, Japan; 3. Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 4. Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, JapanShow moreShow less
Source PDF DOI Publisher page
119 days

Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study

Authors
Ryo Koizumi; Shinsuke Takagi; Aya Nishida; Mika Kuno; Rikako Tabata; Otoya Watanabe; Kyosuke Yamaguchi; Kosei Kageyama; Daisuke Kaji; Yuki Taya; Kazuya Ishiwata; Hisashi Yamamoto; Akiko Masuda; Yukako Koike; Hideki Araoka; Yuki Asano-Mori; Go Yamamoto; Atsushi Wake; Shuichi Taniguchi; Naoyuki UchidaShow moreShow less
Affiliations
1. Department of Hematology, Toranomon Hospital, Tokyo, Japan; 2. Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan; 3. Okinaka Memorial Institute for Medical Research, Tokyo, Japan; 4. Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan; 5. Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 6. Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 7. Department of Clinical Laboratory, Toranomon Hospital, Tokyo, JapanShow moreShow less
Source PDF DOI Publisher page
113 days

Gene editing of hematopoietic stem cells: applications and advances

Authors
Qiuyang Li; Hongxia Wang; Yuqin He; Genyue Hong; Guoxiu BaoShow moreShow less
Affiliations
1. Department of Hematology, Dali Bai Autonomous Prefecture People’s Hospital in Dali, Dali City, ChinaShow moreShow less
Source PDF DOI Publisher page
68 days

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis

Authors
Makoto Kashimura; Yuki Fujioka; Yong-Mei Guo; Teruko Takahashi; Keiichi Moriya; Naoto TakahashiShow moreShow less
Affiliations
1. Division of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan; 2. Division of Central Laboratory, Akita University Hospital, Akita, Japan; 3. Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, JapanShow moreShow less
Source PDF DOI Publisher page
205 days

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study

Authors
Yoshinobu Kanda; Katsuto Takenaka; Tatsu Tanabe; Kazuya Omoto; Kei Kamimura; Kentaro Kudou; Masato KanekoShow moreShow less
Affiliations
1. Division of Hematology, Jichi Medical University, Shimotsuke, Japan; 2. Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University, Matsuyama, Japan; 3. Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan; 4. Yochomachi Clinic, Tokyo, Japan; 5. Takeda Pharmaceutical Company Limited, Osaka, JapanShow moreShow less
Source PDF DOI Publisher page
71 days

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial

Authors
Koji Izutsu; Ayumi Fujimoto; Shinya Rai; Dai Maruyama; Ken Ohmachi; Akihiko Yokohama; Kunihiro Tsukasaki; Toshiki Uchida; Junya Kuroda; Ilseung Choi; Michihiro Hidaka; Jun Ando; Takashi Sakamoto; Hisashi Kato; Hironobu Minami; Shinichiro Yoshida; Matsuo Yamamoto; Mireille Gillings; Hiroshi Onogi; Kengo TakeuchiShow moreShow less
Affiliations
1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan; 2. Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 3. Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 4. Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Sakai, Japan; 5. Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 6. Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan; 7. Department of Hematology, Gunma University Hospital, Maebashi, Japan; 8. Department of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan; 9. Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; 10. Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 11. Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan; 12. Department of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan; 13. Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan; 14. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 15. Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan; 16. Division of Medical Oncology and Hematology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; 17. Department of Hematology, NHO Nagasaki Medical Center, Omura, Japan; 18. Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan; 19. HUYA BIO International, LLC, San Diego, USA; 20. Huya Japan GK, Tokyo, JapanShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.